{"id":1965,"date":"2021-07-26T14:28:42","date_gmt":"2021-07-26T14:28:42","guid":{"rendered":"https:\/\/aisperu.org.pe\/?p=1965"},"modified":"2025-04-14T17:30:25","modified_gmt":"2025-04-14T17:30:25","slug":"vacuna-frente-a-la-covid-19-de-janssen-y-riesgo-de-sindrome-de-guillain-barre","status":"publish","type":"post","link":"https:\/\/aisperu.org.pe\/cms\/vacuna-frente-a-la-covid-19-de-janssen-y-riesgo-de-sindrome-de-guillain-barre\/","title":{"rendered":"Vacuna frente a la COVID-19 de Janssen y riesgo de s\u00edndrome de Guillain-Barr\u00e9"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\">El Comit\u00e9 para la Evaluaci\u00f3n de Riesgos en Farmacovigilancia (PRAC) de la Agencia Europea de Medicamentos (EMA), ha evaluado la informaci\u00f3n disponible sobre el riesgo de aparici\u00f3n de s\u00edndrome de Guillain-Barr\u00e9 (SGB) despu\u00e9s de la administraci\u00f3n de la&nbsp;<a href=\"https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/covid-19-vaccine-janssen#product-information-section\" target=\"_blank\" rel=\"noreferrer noopener\"><strong>vacuna frente a la COVID_19 de Janssen<\/strong><\/a>, incluyendo los casos notificados a nivel mundial en las campa\u00f1as de vacunaci\u00f3n, la informaci\u00f3n procedente de los ensayos cl\u00ednicos y de la literatura cient\u00edfica.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Hasta el 30 de junio se han notificado a nivel mundial 108 casos de SGB tras la administraci\u00f3n de esta vacuna, uno de ellos con desenlace mortal, en el contexto de m\u00e1s de 21 millones de personas vacunadas (de ellos, a fecha 27 de junio, se han notificado 15 en el Espacio Econ\u00f3mico Europeo, con 7 millones de personas vacunadas). En Espa\u00f1a se han registrado tres casos de SGB confirmados hasta el 11 de julio, con cerca de 1,5 millones de dosis administradas.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Acceda a la informaci\u00f3n aqu\u00ed<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><a href=\"https:\/\/www.aemps.gob.es\/informa\/notasinformativas\/medicamentosusohumano-3\/seguridad-1\/2021-seguridad-1\/vacuna-frente-a-la-covid-19-de-janssen-y-riesgo-de-sindrome-de-guillain-barre\/\"><sub>https:\/\/www.aemps.gob.es\/informa\/notasinformativas\/medicamentosusohumano-3\/seguridad-1\/2021-seguridad-1\/vacuna-frente-a-la-covid-19-de-janssen-y-riesgo-de-sindrome-de-guillain-barre\/<\/sub><\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>El Comit\u00e9 para la Evaluaci\u00f3n de Riesgos en Farmacovigilancia (PRAC) de la Agencia Europea de Medicamentos (EMA), ha evaluado la informaci\u00f3n disponible sobre el riesgo de aparici\u00f3n de s\u00edndrome de Guillain-Barr\u00e9 (SGB) despu\u00e9s de la administraci\u00f3n de la&nbsp;vacuna frente a la COVID_19 de Janssen, incluyendo los casos notificados a nivel mundial en las campa\u00f1as de [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":1966,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_coblocks_attr":"","_coblocks_dimensions":"","_coblocks_responsive_height":"","_coblocks_accordion_ie_support":"","_eb_attr":"","hide_page_title":"","footnotes":""},"categories":[7],"tags":[],"class_list":["post-1965","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-noticias"],"_links":{"self":[{"href":"https:\/\/aisperu.org.pe\/cms\/wp-json\/wp\/v2\/posts\/1965","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/aisperu.org.pe\/cms\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/aisperu.org.pe\/cms\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/aisperu.org.pe\/cms\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/aisperu.org.pe\/cms\/wp-json\/wp\/v2\/comments?post=1965"}],"version-history":[{"count":1,"href":"https:\/\/aisperu.org.pe\/cms\/wp-json\/wp\/v2\/posts\/1965\/revisions"}],"predecessor-version":[{"id":5898,"href":"https:\/\/aisperu.org.pe\/cms\/wp-json\/wp\/v2\/posts\/1965\/revisions\/5898"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/aisperu.org.pe\/cms\/wp-json\/wp\/v2\/media\/1966"}],"wp:attachment":[{"href":"https:\/\/aisperu.org.pe\/cms\/wp-json\/wp\/v2\/media?parent=1965"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/aisperu.org.pe\/cms\/wp-json\/wp\/v2\/categories?post=1965"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/aisperu.org.pe\/cms\/wp-json\/wp\/v2\/tags?post=1965"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}